GLSI · Greenwich LifeSciences, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 11, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-29 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
700 |
| 2026-07-28 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2026-07-27 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2026-07-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,100 |
| 2026-07-23 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2026-01-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,800 |
| 2026-01-12 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,900 |
| 2025-12-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,300 |
| 2025-12-30 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,900 |
| 2025-12-18 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,100 |
| 2025-11-25 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,600 |
| 2025-11-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
|
Stock Options
|
100,000 |
| 2025-11-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
10,600 |
| 2025-10-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,300 |
| 2025-04-25 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,600 |
| 2025-04-17 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,400 |
| 2025-04-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,600 |
| 2025-04-04 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,500 |
| 2025-01-10 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2025-01-07 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,800 |
| 2025-01-06 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,100 |
| 2025-01-03 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,400 |
| 2025-01-02 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,000 |
| 2024-12-31 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,400 |
| 2024-12-30 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,200 |
| 2024-12-24 | Hallock Kenneth |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
10,337 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
41,349 |
| 2024-12-24 | Thompson Jaye |
VP Clinical Reg Affairs |
Award↑
Filing footnotes — Stock Options (Direct)
37,455 options are earned upon date of grant and the remainder are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. |
Stock Options
|
149,818 |
| 2024-12-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
Filing footnotes — Stock Options (Direct)
262,181 options are earned upon date of grant and 786,542 options are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. 100,000 options are earned and vest upon date of grant. |
Stock Options
|
1,148,723 |
| 2024-12-24 | Daugherty Frank Joseph |
Director, Chief Medical Officer |
Award↑
Filing footnotes — Stock Options (Direct)
26,233 options are earned upon date of grant and the remainder are earned monthly over 36 months. 10% of the earned options vest if reporting person has been employed by Issuer between 1-2 years from grant date, 20% of the earned options vest if reporting person has been employed by Issuer between 2-3 years from grant date, 30% of the earned options vest if reporting person has been employed by Issuer between 3-4 years from grant date and the remaining earned options vest if reporting person has been employed by Issuer more than 4 years after grant date. |
Stock Options
|
104,890 |
| 2024-12-24 | Rothe Eric |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
10,337 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
41,349 |
| 2024-12-24 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Award↑
Filing footnotes — Stock Options (Indirect)
6,252 options are earned and vest upon date of grant and the remainder are earned and vest monthly over 36 months. |
Stock Options
(I)
|
25,008 |
| 2024-12-24 | McWilliams David |
Director |
Award↑
Filing footnotes — Stock Options (Direct)
15,496 options vest and are exercisable upon date of grant and the remainder vest and are exercisable monthly over 36 months. |
Stock Options
|
61,984 |
| 2024-11-21 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-09-26 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-08-12 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
800 |
| 2024-08-06 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,000 |
| 2024-08-05 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,500 |
| 2024-08-02 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-07-23 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-07-18 | Thompson Jaye |
VP Clinical Reg Affairs |
Buy↑
|
Common Stock
|
1,000 |
| 2024-06-13 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
174,825 |
| 2024-04-01 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,000 |
| 2024-03-22 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
2,500 |
| 2024-03-20 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
1,500 |
| 2024-03-05 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,500 |
| 2024-03-04 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
4,100 |
| 2024-02-16 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
10,800 |
| 2024-02-15 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
12,700 |
| 2023-11-10 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
5,000 |
| 2023-11-03 | Patel Snehal |
Director, CEO and CFO, 10% Owner |
Buy↑
|
Common Stock
|
3,500 |